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Abstract
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide.
Recurrence and metastasis after curative resection remain critical obstacles in HCC treatment. CD146 predicted poor
prognosis of a variety of cancers including melanoma, breast tumors, prostate cancer, and gastric cancer. However,
the role of CD146 in HCC has not yet been systematically explored.
Methods: To investigate the role of CD146 in HCC, we evaluated its expression in HCC tissues and HCC cell lines
using real-time PCR and western blotting (WB). Second, we established HCC cell lines that stably overexpressed and
interfered CD146 and explored the function of CD146 in HCC in vitro and in vivo. Third, we conducted microarray
analysis to investigate the potential mechanism by identifying differentially expressed genes. Last, follow ups were
conducted to help uncover the connection of CD146 expression and the prognosis of HCC patients.
Results: We found that CD146 was overexpressed in HCC tissues and that high CD146 expression predicted poor
overall survival time and shorter recurrence period in HCC patients. In vitro and in vivo experiments indicated that
CD146 promoted migration and invasion of HCC cell lines. Further study indicated that CD146 promoted epithelial
mesenchymal transition (EMT), IL-8 upregulation, and STAT1 downregulation. CD146 was upregulated in HCC
tissues and cell lines.
Conclusions: CD146 promoted metastasis of HCC cells and predicted poor prognosis of HCC patients. CD146
induced EMT, and IL-8 upregulation and STAT1 downregulation may be the potential underlying mechanism. The
exact mechanism still needs further investigation.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignant cancer and the third leading cause of
cancer-related mortality in China [1]. Recurrence and
metastasis after curative resection are the most challen-
ging burdens for HCC treatment [2]. However, the
underlying mechanism of HCC metastasis is largely
unknown.
CD146 was first reported in malignant melanomas [3].
CD146 is a 113-kD membrane glycoprotein that con-
tains five immunoglobulin-like domains, a transmem-
brane region, and a short cytoplasmic tail [4]. Early
research indicated that CD146 expressed in normal tis-
sues is restricted to the blood vessels and smooth muscle
cells [5]. Whereas, subsequent research indicated CD146
is a multifunctional molecule that participates in several
physiological and pathological processes involving in de-
velopment, immunity, and angiogenesis [6]. CD146 me-
diates development of the nervous system, kidney, and
retina [7–9]. Knockdown of CD146 protein expression
hinders vascular development whereas overexpression of
CD146 in zebrafish induces sprouting angiogenesis [10].
CD146 was also found to play a critical role in cancer
progression. In most cancers, CD146 was found to
promote cancer progression, enhanced migration and in-
vasion was observed in melanoma, gallbladder adenocar-
cinoma, breast cancer and prostate cancer [11–14]. In
gastric cancer, lung adenocarcinoma, malignant pleural
mesothelioma, and non-small-cell lung cancer, CD146
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has been identified as an indicator of poor prognosis
[15–18]. However, in oral mucoepidermoid carcinoma,
CD146 expression was greater in intermediate/high
grade tumors, was weaker in patients that presented
local recurrence, regional and distant metastasis [19].
Most researches above focused on relationship between
CD146 expression and clinical outcomes, the underlying
mechanism of CD146 induced migration and invasion
has not yet been systemically explored. the mechanism
besides CD146 induced angiogenesis was rarely ex-
plored. In HCC research, CD146 was reported to be
used as endothelial marker in selective targeting of liver
cancer treatment [20]. The role of CD146 in HCC cells
has not yet been explored.
In this study, we set out to investigate the role of
CD146 in HCC. We mainly focused on the CD146 on
tumor cells whereas the role of CD146 in endothelial
cells was not addressed. Firstly, the expression of CD146
in HCC tissues and HCC cell lines was detected using
RT-PCR and WB, the location of CD146 was confirmed
using IHC; Secondly, we established in vitro and in vivo
models to investigate the biologic function of CD146 in
HCC cells; Thirdly, we conducted a mRNA microarray
to systemically explore the mechanism of CD146 in-
duced biologic behavior variation of HCC cells; lastly,
CD146 expression and clinical prognosis of HCC pa-
tients was concerned.
Methods
Cell lines and cell culture
Cell lines used in this study include eight human
HCC cell lines, MHCC-97H, MHCC-97 L, HepG2,
SMMC-7721, Focus, YY-8103, LM3, and HLF, and
one human noncancerous hepatic cell line, L02. All
these cell lines were provided and identified by our
key laboratory of living donor liver transplantation.
All cells were cultured in Dulbecco’s Modified Eagle
medium (Gibco, Grand Island, NY, USA) containing
10 % FBS (Hyclone, Logan, UT, USA), 100 U/mL
penicillin and 100 μg/mL streptomycin (Invitrogen,
Carlsbad, CA, USA) at 37 °C in 5 % CO2.
Patients and follow-up
A total of 120 HCC samples and homologous noncan-
cerous tissue samples were randomly obtained from the
samples that were removed from the patients and stored
in the department of pathology between June 2008 and
May 2010, snap frozen in liquid nitrogen, and stored at
−80 °C until use. All samples were subjected to routine
pathological examination at the First Affiliated Hospital
of Nanjing Medical University. All patients underwent
curative resection of HCC at the First Affiliated Hospital
of Nanjing Medical University (Nanjing, China). The pa-
tients’ age ranged from 31 to 83 years. Detailed
clinicopathological characteristics of the 120 HCC pa-
tients are listed in Table 1. Written informed consent
was obtained from each patient before surgery. The pa-
tients were followed up after surgical treatment until
August 2014. This study was approved by the Ethics
Committee of the First Affiliated Hospital of Nanjing
Medical University.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from tissue samples and cell
lines using Trizol Reagent (Takara, Dalian, China). RNA
concentrations and quality were determined with a
NanoDrop ND-2000 spectrophotometer (NanoDrop
Technologies, IL, USA) and gel analysis. Reverse tran-
scription was performed using PrimeScript® RT Reagent
Kit (Takara). Real-time polymerase chain reaction (RT-
PCR) amplifications were carried out on ABI stepone
RT-PCR Detection System (ABI, Carlsbad, CA, USA)
using the SYBR Green PCR detection kit (Takara) ac-
cording to the manufacturer’s introductions. Primers are
summarized in Table S1 (Additional file 1). The cycle
time (Ct) values of the selected genes were first normal-
ized with the value of beta actin of the same sample, and
then the relative expression of each gene was analyzed
using the 2-ΔΔCt method.
Western blotting
Western blotting was performed using standard tech-
niques as previously described [11]. Briefly, total protein
was extracted using RIPA lysis buffer (50 mM Tris-Cl
pH 7.4, 150 mM NaCl, 0.5 % sodium deoxycholate, 1 %
NP-40, 0.1 % SDS, 1 mM EDTA, 100 mM NaF, 1 mM
Na3VO4, 1 mM PMSF, and 2 μg/mL aprotinin) on ice.
Protein samples (50 μg) were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride membranes.
Membranes were blocked with 5 % nonfat milk in TBST
(10 mM Tris, pH 7.4, 150 mM NaCl, and 0.1 % Tween-
20) at room temperature for 1 h and incubated with in-
dicated primary antibodies at 4 °C overnight with gentle
rocking. After washing with TBST, the membrane was
incubated with the appropriate HRP-conjugated second-
ary antibodies for 1 h at 37 °C. After extensive washing
with TBST, proteins were visualized by the enhanced
chemiluminescence detection kit in accordance with the
manufacturer’s recommendations (Thermo Fisher scien-
tific, MA , USA). Antibodies used in this study are sum-
marized in Table S2 (Additional file 2).
Immunohistochemistry
Immunohistochemical staining was performed using the
diaminobenzidine detection kit (Maixin-Bio, Fuzhou,
China) following the manufacturer’s instructions. Briefly,
human hepatocellular carcinoma tissues with matched
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peritumor tissues were processed by standard histo-
logical techniques. Tissue sections were deparaffinized
and rehydrated. Then, sections were heated in a pressure
cooker for 2 min to repair antigenicity and were treated
with 3 % H2O2 for 10 min to inactivate endogenous per-
oxidase activity and incubated with goat serum for
10 min to block nonspecific antibody binding. Sections
were incubated with a primary antibody at 37 °C for 1 h,
a biotin-labeled secondary antibody for 10 min, and
streptavidin-peroxidase conjugate for 10 min. A solution
of 0.02 % iaminobenzidine was used as chromogen to
visualize peroxidase activity. The sections were lightly
counterstained with hematoxylin, mounted with Permount,
and examined by light microscopy.
Establishment of stable cell clones
Lentiviruses overexpressing CD146 (Lv-CD146) or silencing
CD146 (Lv-shCD146) were purchased from Genechem
(Shanghai, China). The sequence of interfere chain
was listed in Table S3 (Additional file 3). Lentivirus
was infected into HCC cells with a multiplicity of in-
fection (MOI) ranging from 5 to 20 in the presence
of polybrene (10 μg/mL). Low CD146 expressing cell
lines MHCC-97 L and HLF were infected with Lv-
CD146, defined as 97 L-CD146 and HLF-CD146.
High CD146 expressing cell lines MHCC-97H and
SMMC-7721 were infected with Lv-shCD146, defined
as 97H-shCD146 and 7721-sh-CD146. At 72 h after
infection, cells were selected for 1 week using puro-
mycin (5 μg/mL). The selected cell lines were pre-
pared for subsequent experiments.
Transwell cell migration and invasion assays
Transwell chambers with an 8-μm pore size were used
to measure migration and invasion ability of HCC cells.
For migration assays, 5 × 104 cells in 250 μL DMEM
containing 0.2 % FBS were seeded into the upper cham-
ber and 500 μL DMEM containing 10 % FBS was added
Table 1 Clinical characteristics of HCC patients and correlation with CD146 level
Clinical characteristics Patients (n = 120) CD146 High CD146 low P value
Age(Y) ≥ 50 41 42
< 50 17 20 0.727
Sex Male 52 54
Female 6 8 0.663
HBsAg Positive 51 60
Negative 7 2 0.136a
Child-Pugh score A 56 61
B 2 1 0.953a
Liver cirrhosis Yes 51 57
No 7 5 0.465
AFP (ng/ml) ≥ 400 39 27
< 400 19 35 0.009
Tumor number single 45 51
multiple 13 11 0.523
Tumor size (cm) ≥ 5 42 43
< 5 16 19 0.713
Vascular invasion Yes 24 13
No 34 49 0.016
Satellite lesion Yes 13 5
No 45 57 0.028
Tumor encapsulation Complete 27 42
None 31 20 0.019
Edmondson stage I-II 20 37
III-IV 38 25 0.006
Recurrence Yes 47 23
No 11 39 <0.001
Abbreviations: HBsAg Hepatitis B surface antigen, AFP α-fetoprotein, HCC hepatocellular carcinoma
aContinuous correction
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to the lower chamber. For invasion assays, the upper
chamber was pre-coated with 50 μL 1:1 mixture of
Matrigel (BD Biosciences, USA) and DMEM overnight
before 1 × 105 cells were seeded. Cells were incubated in
5 % CO2 at 37 °C for 24 h (migration) or 72 h (invasion),
Then, cells on the upper side of well were removed, the
wells were fixed in methanol for 20 min, and crystal vio-
let was used to stain cells. Photographs of five random
fields were captured for quantification analysis. Three
identical replicates were performed.
Animals
Male nude mice (4–6 weeks old) were purchased from
Yangzhou University and housed in Nanjing Agricultural
University under specific pathogen-free conditions and
cared for according to the institutional guidelines for
animal care. All animal experiments met the National
Institutes of Health guidelines and were approved by the
Committee on the Ethics of Animal Experiments of
Nanjing Medical University.
In vivo metastasis assays
A total of 5 × 106 tumor cells were suspended in
100 μL DMEM and then injected subcutaneously into
the upper right flank region of nude mice. When the
subcutaneous tumor reached approximately 1 cm in
length (approximately 2–4 weeks after injection), it
was removed, minced into small pieces of equal vol-
ume (1 mm3), and implanted into the livers of nude
mice (10 per group). All mice were monitored once
every 3 days, and six mice of each group were sacri-
ficed 6 weeks later. The liver and lung tissues were
dissected, fixed with 4 % phosphate-buffered neutral
formalin, and prepared for histological examination.
All metastatic foci in the lung were calculated micro-
scopically to evaluate the development of pulmonary
metastasis.
Microarray processing and analysis
Total RNA was isolated from HLF-vec (n = 3) and HLF-
CD146 (n = 3) cell lines. RNA samples were analyzed by
microarray expression profiling using the Affymetrix
Human GeneChip primeview (Affymetrix) according to
the manufacturer’s instructions. Briefly, cDNA target
preparation and in vitro transcription were conducted
using the GeneChip 3′IVT PLUS Kit. Arrays were
washed, stained, and processed using the GeneChip
Hybridization Wash and Stain Kit, after which they were
imaged using the Affymetrix GeneChip Scanner 3000
for subsequent generation of raw data. Genes signifi-
cantly differentially expressed between HLF-vec and
HLF-CD146 cells were selected based on fold change
>1.5 and P < 0.05. Functional pathway analysis was con-
ducted using KEGG pathway enrichment analysis and
gene ontology analysis according to the manufacturer’s
instructions.
Statistical analysis
Statistical analyses were performed using SPSS 18.0
(SPSS, Chicago, IL, USA) or Prism 5.0 (GraphPad
Software, La Jolla, CA, USA) software. The results
were presented as the mean ± standard error of mean.
Quantitative data were performed by the two-tailed
Student’s t-test. Categorical data were analyzed by χ2
test. Kaplan–Meier and log-rank analysis was used to
assess the survival between subgroups. P < 0.05 was
considered statistically significant.
Results
The expression of CD146 is upregulated in HCC
To investigate the role of CD146 in HCC, we first ex-
plored the expression of CD146 in HCC tissues and
HCC cell lines. We examined CD146 mRNA levels in
120 paired HCC and peritumoral samples using RT-
PCR and found that the average expression level of
CD146 was significantly higher in HCC than that in
peritumoral tissues (Fig. 1a). The upregulation of
CD146 was confirmed in 20 paired samples randomly
obtained from the 120 paired HCC samples using
WB (Fig. 1b (3 pairs) and d, and Additional file 4:
Figure S1 (17 pairs)). Immunohistochemical assays re-
vealed that CD146 was located on the membrane of
HCC cells (Fig. 1c). CD146 expression was also ob-
served in vascular endothelial cells with much lower
intensity, no expression was observed in normal liver
cells or other cirrhotic tissue. We then performed
RT-PCR and WB to investigate the expression of
CD146 in HCC cell lines and noncancerous liver cell
lines. We found that the expression of CD146 was
markedly upregulated in several HCC cell lines com-
pared with noncancerous cell lines (Fig. 2a and d).
Taken together, these data indicated that CD146 is
expressed in HCC cells, the expression of CD146 is
upregulated in HCC.
CD146 promotes migration and invasion of HCC cell lines
To determine the biological function of CD146 in HCC,
we first established HCC cell lines that stably overex-
press or repress CD146 expression using lentivirus as a
vehicle. We overexpressed CD146 in 97 L and HLF cells,
which are low CD146-expressing cell lines, by lentiviral
particles that overexpresses CD146 and renamed these
cell lines as 97 L-CD146 and HLF-CD146 (Fig. 2b and
e). We also knocked down CD146 in 97H and
SMMC7721 cells, which are high CD146-expressing cell
lines, using lentiviral particles that expresses CD146
shRNA, and renamed these cells as 97H-shCD146 and
SMMC7721-shCD146 (Fig. 2c and f). We then assessed
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Fig. 1 CD146 up-regulated in HCC Patients. a RT-PCR of 120 paired HCC and peritumor tissues (***P < 0.001). b Western Blotting of 3 paired HCC
and peritumor tissues. c IHC of the location of CD146 is expressed on the membrane of HCC cells (black arrow). d Gray scale analysis of averaged
CD146/GAPDH in b (n = 3,**P < 0.01)
Fig. 2 Construction of HCC cell lines stably overexpress or interfere CD146 expression. a Western Blot analysis of CD146 in HCC cell lines.
b Construction of high CD146 expression cell lines. c Construction of low CD146 expression cell lines. d Gray scale analysis of CD146/GAPDH in
a (n = 3). e Gray scale analysis of CD146/GAPDH in B (n = 3, ***P < 0.001). f Gray scale analysis of CD146/GAPDH in c (n = 3, ***P < 0.001)
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the effects of CD146 on cell growth, migration, invasion,
apoptosis and cell cycle. No obvious differences were ob-
served in cell growth (Additional file 5: Figure S2), apop-
tosis, or cell cycle (Additional file 6: Figure S3) among
all the experimental cells. However, transwell assays
demonstrated that upregulation of CD146 expression
significantly enhanced the migration and invasion cap-
acities of 97 L-CD146 (Fig. 3a) and HLF-CD146 cells
(Fig. 3b). Consistent with these data, CD146 repression
in 97H-shCD146 (Fig. 3c) and SMMC7721-shCD146
cells (Fig. 3d) significantly reduced cell migration and in-
vasion. These results indicated that CD146 promotes
migration and invasion of HCC cells in vitro.
We further examined the role of CD146 in HCC me-
tastasis by establishing an orthotropic tumor metastasis
model in nude mice, which closely mimics the process
of human HCC metastasis after the formation of the pri-
mary foci. Histological analysis of liver tissues revealed a
significant effect of CD146 in local invasion of the HCC
tumors in the livers. The tumors of the high-CD146 ex-
pressing HCC groups (97H-vec and 7721-CD146) had
more frequent invasive growth fronts with irregular
tumor borders, whereas those of the low-CD146 ex-
pressing HCC groups (7721-vec and 97H-shCD146)
showed less invasive foci and regular tumor borders.
Histological analysis of lung tissue showed that the inci-
dence of lung metastasis in the high CD146-expressing
HCC groups was significantly higher than that in the
low CD146-expressing HCC groups (Fig. 4). Taken to-
gether, these data confirmed that CD146 promotes mi-
gration and invasion of HCC cell lines.
CD146 promotes EMT and IL-8 upregulation and STAT1
downregulation
To uncover the mechanism underlying CD146-
induced migration and invasion, we conducted a
microarray analysis to identify genes whose expression
was modified by CD146 upregulation using HLF-vec
and HLF-CD146 cell lines (Fig. 5a). A total of 131
genes were upregulated and 365 genes were downreg-
ulated after CD146 overexpression (P < 0.05 and fold
change >1.5). Supervised analysis was conducted fol-
lowing KEGG and the Gene Ontology technical route.
We focused on cancer-related pathways and found
that 16 genes showed modified expression upon
CD146 overexpression (Additional file 7: Table S4). A
network diagram was drawn to show the potential
connection between each gene (Fig. 5b).
Further verification was conducted using western blot-
ting. Interlukin-8 (IL-8) was upregulated whereas signal
Fig. 3 In vitro migration and invasion assays. a Overexpression of CD146 in 97 L enhanced cell migration and invasion in transwell assays (n = 3,
*P < 0.05, **P < 0.01). b Overexpression of CD146 in HLF enhanced cell migration and invasion in transwell assays (n = 3, **P < 0.01, ***P < 0.001).
c Inhibition of CD146 in 97H decreased cell migration and invasion in transwell assays (n = 3, **P < 0.01, ***P < 0.001). d Inhibition of CD146 in
SMMC-7721 decreased cell migration and invasion in transwell assays (n = 3, *P < 0.05, **P < 0.01)
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transducer and activator of transcription 1 (STAT1) was
downregulated after CD146 overexpression (Fig. 6a) and
the opposite effects were observed upon CD146 down-
regulation (Fig. 6b). Pathway analysis indicated that
mitogen activated protein kinase 1 (MAPK1) may be the
potential pathway by which CD146 induced IL-8 and
STAT1 modification. We confirmed that phosphoryl-
ation of MAPK1 [Alternative Name: extracellular signal
regulated kinase 1 and 2 (ERK1/2)] was markedly
increased after CD146 overexpression (Fig. 6a) and de-
creased after CD146 downregulation (Fig. 6b).
We also tested migration-associated EMT markers
and found that E-cadherin was downregulated and
vimentin and slug were upregulated in the CD146 over-
expressed HCC cells (Fig. 6c). Interfering with CD146
expression showed the opposite results (Fig. 6d).
Taken together, these data indicated that CD146 may
regulate IL-8 to activate the MAPK1 signaling pathway,
Fig. 4 In vivo metastasis assays using orthotropic tumor metastasis model. a HCC cell lines with high CD146 indicated more frequent metastasis
nodules in liver (40X vs 200X). b HCC cell lines with high CD146 indicated more frequent metastasis nodules in lung (40X vs 200X). c statistical
analysis of liver and lung metastasis
Fig. 5 Mechanism analysis of CD146 induced metastasis. a A 3 × 3 DNA microarray of HLF-vec and HLF-CD146. A total of 496 genes were found
modified after CD146 overexpression (P < 0.05 and fold change >1.5). b GO analysis of potential regulatory mechanisms of CD146
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and further regulate STAT1 and EMT to promote mi-
gration and invasion of HCC cell lines.
CD146 predicted poor prognosis of HCC patients
We also followed up HCC patients in this study. 120 pa-
tients were divided into CD146 high group (n = 58) and
CD146 low group (n = 62) according to their relative
CD146 mRNA expression, averaged 2^-ΔCT value was
used as a cut off point. Patient demographics were listed
in Table 1. By the time of analysis, recurrence had oc-
curred in 70 of 120 patients, with a mean follow-up time
of 38.0 ± 2.1 months (median, 23.0 months; range, 6.0–
73.0 months). Among these 70 patients, 58 had intrahe-
patic recurrence only, 5 had lung metastasis only, and 7
suffered both intrahepatic recurrence and lung
metastasis.
Recurrence was observed in 43 of 70 patients with
high CD146, while only 27 of 73 patients with low
CD146. Among 12 patients who developed lung me-
tastasis, 9 patients had high CD146. In addition,
CD146 high group were more likely to manifest high
AFP level (P = 0.009), vascular invasion (P = 0.016),
satellite lesions (P = 0.028), no tumor encapsulation
(P = 0.019), poor tumor differentiation (P = 0.006), and
higher recurrence (P < 0.001, Table 1).
Using a averaged 2^-ΔCT value of CD146 mRNA ex-
pression as the cutoff value in univariate analysis, pre-
operative CD146 mRNA expression showed prognostic
significance for TTR (time to recurrence) (P = 0.001,
Fig. 6 Western blotting vertification of the mechanism of CD146 induced metastasis. a CD146 induced ERK1/2 phosphorylation, IL-8 upregulation
and STAT1 down regulation in HLF and 97 L cell lines (n = 3, **P < 0.01, ***P < 0.001). b Interfere CD146 inhibited ERK1/2 phosphorylation, induced
IL-8 downregulation and STAT1 upregulation in 97H and 7721 cell lines (n = 3, **P < 0.01, ***P < 0.001). c CD146 induced EMT (E-cad downregulation,
vimentin, slug upregulation ) in HLF and 97 L cell lines (n = 3, **P < 0.01, ***P < 0.001). d Interfere CD146 inhibited EMT in 97H and 7721 cell lines
(n = 3, **P < 0.01, ***P < 0.001)
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Table 2). Patients in CD146 high group had significantly
shorter TTR (median, 9.0 months vs. not reached) and
higher recurrence rates (81.0 % vs. 37.1 %) than those in
Patients in CD146 low group (P < 0.001, Fig. 7a). Levels
of AFP, tumor number, vascular invasion, satellite lesion,
tumor encapsulation and Edmondson stage were also
unfavorable prognostic variables for recurrence (all P
values of <0.05, Table 2). In multivariate analysis, high
CD146 mRNA expression was the strongest independent
prognostic factor for TTR [hazard ratio (HR) =2.49;
95 % confidence interval (CI), 2.43–4.00, P < 0.001;
Table 2].
Patients in CD146 high group had obvious higher re-
currence probability and shorter overall survival time
than those in CD146 low group (Fig. 7a and b). This
finding enrolled CD146 with clinical significance.
Targeting CD146 may become a potential therapeutic
strategy of HCC treatment.
Discussion
In this study, we demonstrate for the first time that
CD146 promotes HCC progression. We confirmed this
finding by providing the following evidence. First,
CD146 was frequently upregulated in human HCC tis-
sues compared with adjacent noncancerous tissues and a
high CD146 level predicted high recurrence probability
and poor overall survival time. Second, in vitro experi-
ments showed that overexpression of CD146 in low
CD146-expressing HCC cell lines markedly promoted
cell migration and invasion whereas interfering with
CD146 expression in high CD146-expressing HCC cell
lines showed opposite results. In vivo experiments using
Table 2 Univariate and multivariate Cox proportional regression analysis of factors associated with recurrence
Variables Univariate analysis Multivariate analysis
HR (95 % CI) P HR (95 % CI) P
Age (> 50yvs. ≤ 50y) 0.90 (0.55–1.48) 0.673 N.A. N.A.
Sex (male vs. female) 1.01 (0.48–2.10) 0.990 N.A. N.A.
HBsAg (Positive vs. Negative) 0.77 (0.33–1.77) 0.536 N.A. N.A.
Child-Pugh score (A vs. B) 1.12 (0.27–4.55) 0.879 N.A. N.A.
Liver cirrhosis (Yes vs. No) 0.99 (0.45–2.16) 0.977 N.A. N.A.
AFP (> 400 ng/ml vs. ≤ 400 ng/ml) 1.73 (1.06–2.81) 0.027 1.30 (0.78–2.16) 0.309
Tumor number (Multiple vs. Single) 1.77 (1.04–3.00) 0.022 1.42 (0.82–2.48) 0.214
Tumor size (> 5 cm vs. ≤ 5 cm) 1.35 (0.79–2.31) 0.273 N.A. N.A.
Vascular invasion (Yes vs. No) 2.16 (1.34–3.48) 0.002 1.14 (0.68–1.93) 0.621
Satellite lesion (Yes vs.No) 2.92 (1.66–5.16) 0.001 1.96 (1.06–3.63) 0.032
Tumor encapsulation (Yes vs. No) 2.26 (1.40–3.63) 0.001 1.64 (0.99–2.71) 0.054
Edmondson stage (III-IV vs. I-II) 2.15 (1.31–3.52) 0.003 1.75 (1.05–2.93) 0.032
CD146 (High vs. LOW) 3.64 (2.20–6.03) <0.001 2.49 (2.43–4.00) 0.001
Abbreviations: HBsAg Hepatitis B surface antigen, AFP α-fetoprotein
Fig. 7 CD146 predicted poor prognosis of HCC patients. a Patients in comparative CD146 high group (n = 62) had higher recurrence rate than
those in comparative CD146 low group (n = 58) (P <0.001). b patients in comparative CD146 high group (n = 62) had lower overall survival time
than those in comparative CD146 low group (n = 58) (P < 0.001)
Jiang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:38 Page 9 of 12
the orthotropic tumor metastasis model confirmed these
results; more intraliver invasion nodules and lung meta-
static foci were observed with CD146 overexpressing cell
lines and the opposite effects were observed with CD146
silenced cell lines.
We further investigated the potential mechanisms of
CD146-induced migration and invasion by whole gen-
ome DNA microarrays and WB validation. We found
that STAT1 was downregulated whereas IL-8 was upreg-
ulated after CD146 overexpression. Although a few re-
ports indicated STAT1 promoted cancer progression
[21, 22], it has been widely accepted that STAT1 nega-
tively regulates cancer progression. STAT1 negatively
regulates angiogenesis, tumorigenicity, and metastasis of
tumor cells by inhibiting the expression of bFGF, MMP-
2, and MMP-9 [23]. STAT1 also functions as a suppres-
sor of HCC cell proliferation and a regulator of HCC cell
apoptosis by regulating p53 and cyclin E expression [24].
IL-8 was first identified as a chemotactic factor for leu-
kocytes and was demonstrated to function in cancer
progression over recent decades. Serum IL-8 was found
upregulated in HCC patients and was correlated with
larger tumor volume and advanced tumor stage. IL-8
promoted HCC invasion and the incidence of micro-
scopic vessel invasion was significantly higher in IL-8-
positive than in IL-8-negative HCC tissues. Further
investigation indicated that IL-8 may function by pro-
moting EMT [25–27]. In this study, STAT1 was
downregulated and IL-8 was upregulated after CD146
overexpression. Because previous studies showed that
STAT1 and IL-8 could regulate HCC metastasis, to-
gether these data indicate that CD146 could promote
HCC metastasis by, or at least partially by, regulating
STAT1 and IL-8. However, the precise mechanism of
the regulation process still needs further investigation.
Second, CD146 was reported to promote metastasis by
regulating EMT in other solid tumors such as breast
tumor [13, 28]. EMT was believed to endow cancer cells
with migratory and invasive properties and induce can-
cer stem cell properties [29, 30]. However, whether
CD146 could induce EMT in HCC has never been
explored. We found that CD146 induced E-cadherin
loss and vimentin and slug overexpression, and this
phenomenon reversed after CD146 inhibition. This in-
dicated that CD146-induced EMT may also count for
CD146-induced metastasis of HCC cell lines.
Last, we investigated the potential signaling path-
way of CD146-induced metastasis. According to Gene
Ontology analysis, a MAPK1-associated signaling pathway
was indicated to play a central role. We confirmed that
MAPK1 was phosphorylated after CD146 overexpression
and the opposite effects were observed after CD146 down-
regulation. MAPKs are generally expressed in all cell types
and transduce stimulations, growth factors, cytokines, and
extracellular stress signals into intracellular responses
[31]. MAPK1 is one of the subfamilies of MAPKs that
functions in various physiological and pathological pro-
cesses. The role of MAPK1 in cancer development has
also been widely explored. MAPK1 phosphorylation was
involved in S100p-induced proliferation and metastasis, as
well as EMT in colon cancer [32]. The insulin-like growth
factor binding protein 5 inhibited MAPK1, resulting in
compromised growth and migration ability in melanoma
cells [33]. Scribble acts as an oncogene in Eμ-myc-driven
lymphoma, and the potential mechanism partially involves
the activation of MAPK1 [34]. In HCC development, sim-
ultaneous activation of the MAPK1 pathways has been
shown to enhance cell-cycle progression [35]. Recently,
EDIL3 was identified to promote angiogenesis, metastasis,
and recurrence of HCC by MAPK1 and TGF-β signaling
pathways [36]. These studies indicate the pivotal role of
MAPK1 in cancer progression, especially in cancer metas-
tasis and EMT.
Conclusion
In conclusion, our findings show that CD146 promotes
migration and invasion of HCC cell lines by regulating
EMT. CD146-induced IL-8 upregulation and further
activation of MAPK1 signaling pathways may be its po-
tential regulating methods. However, unraveling the de-
tailed signaling pathways involved in CD146-induced
EMT will require further research. In recent years, circu-
lating cancer cell research has Enrich the means to
detect tumor cells [37, 38], and the potential of CD146
on circulating tumor cell research still need further
investigation.
To our knowledge, this is the first report to identify
the striking correlation between high CD146 expression
and poor prognosis of HCC patients. Furthermore, we
demonstrated that CD146 plays a critical role in HCC
progression by MAPK1 signaling dependent EMT activa-
tion. Our results indicate that CD146 can be used as a
potential HCC marker and may therefore be helpful in
developing an effective treatment against cancer.
Additional files
Additional file 1: Table S1. Primer pairs used for real-time PCR in this
study. (DOCX 12 kb)
Additional file 2: Table S2. Antibodies used in this study. (DOCX 13 kb)
Additional file 3: Table S3. CD146 interfere sequence used in this
study. (DOCX 12 kb)
Additional file 4: Figure S1. Western Blotting of 17 paired HCC and
peritumor tissues. (TIF 6418 kb)
Additional file 5: Figure S2. CD146 expression doesn’t impact cell
proliferation in 97H or 97 L cell lines. (TIF 5396 kb)
Additional file 6: Figure S3. CD146 expression doesn’t impact
apoptosis and cell cycle in 97H or 97 L cell lines. (TIF 6329 kb)
Jiang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:38 Page 10 of 12
Additional file 7: Table S4. Cancer related pathway genes modulated
after CD146 upregulation. (DOCX 13 kb)
Abbreviations
EMT: epithelial mesenchymal transition; ERK1/2: extracellular signal regulated
kinase 1 and 2; HCC: hepatocellular carcinoma; IL-8: interleukin-8; MAPK
1: mitogen activated protein kinase 1; RT-PCR: real-time polymerase chain
reaction; STAT1: signal transducer and activator of transcription 1; TTR: time
to recurrence; WB: western blotting.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GJ and LZ contributed equally to this work. GJ, LZ, QZ, DB, CZ and XW
carried out all the experiments, prepared figures and drafted the manuscript.
GJ, LZ, CZ and XW participated in data analysis and interpretation of results.
GJ and XW designed the study, participated in data analysis and
interpretation of results. All authors read and approved the manuscript.
Acknowledgements
This work was supported by the National Natural Science Foundation of
China (Grant No. 81470901 and No. 81270553).
Author details
1Department of Hepatobiliary Surgery, Clinical Medical College of Yangzhou
University, Yangzhou, P.R. China. 2Key Laboratory of Living Donor Liver
Transplantation, Ministry of Public Health; Department of Liver
Transplantation Center, The First Affiliated Hospital of Nanjing Medical
University, Nanjing, P.R. China.
Received: 22 December 2015 Accepted: 24 February 2016
References
1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H. Cancer statistics in China,
2015. CA Cancer J Clin. 2016. doi:10.3322/caac.21338.
2. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent
advances. Hepatobiliary Pancreat Dis Int. 2008;7:237–57.
3. Lehmann JM, Riethmüller G, Johnson JP. MUC18, a marker of tumor
progression in human melanoma, shows sequence similarity to the neural
cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad
Sci U S A. 1989;86:9891–5.
4. Sers C, Kirsch K, Rothbächer U, Riethmüller G, Johnson JP. Genomic
organization of the melanoma-associated glycoprotein MUC18: implications
for the evolution of the immunoglobulin domains. Proc Natl Acad Sci
U S A. 1993;90:8514–8.
5. Sers C, Riethmüller G, Johnson JP. MUC18, a Melanoma-Progression
Associated Molecule, and Its Potential Role in Tumor Vascularization and
Hematogenous Spread. Cancer Res. 1994;54:5689–94.
6. Wang Z, Yan X. CD146, a multi-functional molecule beyond adhesion.
Cancer Lett. 2013;330:150–62.
7. Taira E, Kohama K, Tsukamoto Y, Okumura S, Miki N. CD146 is
involved in neurite extension of NGF-treated PC12 cells. J Cell Physiol.
2005;204:632–7.
8. Takaha N, Taira E, Taniura H, Nagino T, Tsukamoto Y, Matsumoto T, et al.
Expression of gicerin in development, oncogenesis and regeneration of the
chick kidney. Differentiation. 1995;58:313–20.
9. Tsukamoto Y, Taira E, Nakane Y, Tsudzuki M, Kohama K, Amin H, et al.
Expression of gicerin, a cell adhesion molecule, in the abnormal retina in
silver plumage color mutation of Japanese quail (Coturnix japonica).
Neurosci Lett. 1999;266:53–6.
10. Chan B, Sinha S, Cho D, Ramchandran R, Sukhatme VP. Critical roles of
CD146 in zebrafish vascular development. Dev Dyn. 2005;232:232–44.
11. Lei X, Guan CW, Song Y, Wang H. The multifaceted role of CD146/MCAM in
the promotion of melanoma progression. Cancer Cell Int. 2015;15:3.
12. Wang W, Yang ZL, Liu JQ, Jiang S, Miao XY. Identification of CD146
expression, angiogenesis, and lymphangiogenesis as progression, metastasis
and poor-prognosis related markers for gallbladder adenocarcinoma.
Tumour Biol. 2012;33:173–82.
13. Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, et al.
CD146 expression is associated with a poor prognosis in human breast
tumors and with enhanced motility in breast cancer cell lines. Breast Cancer
Res. 2009;11:R1.
14. Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, et al. Isolation and
characterization of the major form of human MUC18 cDNA gene and
correlation of MUC18 overexpression in prostate cancer cell lines and
tissues with malignant progression. Gene. 2001;279:17–31.
15. Liu WF, Ji SR, Sun JJ, Zhang Y, Liu ZY, Liang AB, et al. CD146 Expression
Correlates with Epithelial-Mesenchymal Transition Markers and a Poor
Prognosis in Gastric Cancer. Int J Mol Sci. 2012;13:6399–406.
16. Oka S, Uramoto H, Chikaishi Y, Tanaka F. The expression of CD146 predicts a
poor overall survival in patients with adenocarcinoma of the lung.
Anticancer Res. 2012;32:861–4.
17. Sato A1, Torii I, Okamura Y, Yamamoto T, Nishigami T, Kataoka TR, et al.
Immunocytochemistry of CD146 is useful to discriminate between
malignant pleural mesothelioma and reactive mesothelium. Mod Pathol.
2010;23:1458–66.
18. Kristiansen G, Yu Y, Schlüns K, Sers C, Dietel M, Petersen I. Expression of the
cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal
Cell Pathol. 2003;25:77–81.
19. Pires FR, Shih IM, da Cruz Perez DE, de Almeida OP, Kowalski LP. Mel-CAM
(CD146) expression in parotid mucoepidermoid carcinoma. Oral Oncol.
2003;39:277–81.
20. Thomann S, Longerich T, Bazhin AV, Mier W, Schemmer P, Ryschich E.
Selective targeting of liver cancer with the endothelial marker CD146.
Oncotarget. 2014;5:8614–24.
21. Malilas W, Koh SS, Kim S, Srisuttee R, Cho IR, Moon J, et al. Cancer
upregulated gene 2, a novel oncogene, enhances migration and drug
resistance of colon cancer cells via STAT1 activation. Int J Oncol.
2013;43(4):1111–6.
22. Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, et al.
STAT1 pathway mediates amplification of metastatic potential and
resistance to therapy. PLoS One. 2009;4(6):e5821.
23. Huang S, Bucana CD, Van Arsdall M, Fidler IJ. Stat1 negatively regulates
angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene.
2002;21:2504–12.
24. Chen G, Wang H, Xie S, Ma J, Wang G. STAT1 negatively regulates
hepatocellular carcinoma cell proliferation. Oncol Rep.
2013;29:2303–10.
25. Ren Y, Poon RT, Tsui HT, Chen WH, Li Z, Lau C, et al. Interleukin-8 serum
levels in patients with hepatocellular carcinoma: correlations with
clinicopathological features and prognosis. Clin Cancer Res.
2003;9:5996–6001.
26. Kubo F, Ueno S, Hiwatashi K, Sakoda M, Kawaida K, Nuruki K. Interleukin 8 in
human hepatocellular carcinoma correlates with cancer cell invasion of
vessels but not with tumor angiogenesis. Ann Surg Oncol. 2005;12:800–7.
27. Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ, Zhou SL, et al. Macrophage-
secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular
carcinoma cells by activating the JAK2/STAT3/Snail pathway. Int J Oncol.
2015;46:587–96.
28. Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, et al. CD146, an epithelial-
mesenchymal transition inducer, is associated with triple-negative breast
cancer. Proc Natl Acad Sci U S A. 2012;109:1127–32.
29. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal
transitions in development and disease. Cell. 2009;139:871–90.
30. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The
epithelial-mesenchymal transition generates cells with properties of stem
cells. Cell. 2008;133:704–15.
31. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al.
Mitogen-activated protein (MAP) kinase pathways: regulation and
physiological functions. Endocr Rev. 2001;22:153–83.
32. Shen Z, Deng H, Fang Y, Zhu X, Ye GT, Yan L, et al. Identification of the
interplay between SOX9 and S100P in the metastasis and invasion of colon
carcinoma. Oncotarget. 2015;6:20672–84.
33. Wang J, Ding N, Li Y, Cheng H, Wang D, Yang Q, et al. Insulin-like growth
factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human
melanoma cells. Oncotarget. 2015;6:20636–49.
34. Hawkins ED, Oliaro J, Ramsbottom KM, Newbold A, Humbert PO, Johnstone
RW, et al. Scribble acts as an oncogene in Emu-myc-driven lymphoma.
Oncogene. 2015. doi:10.1038/onc.2015.167.
Jiang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:38 Page 11 of 12
35. Chin R, Earnest-Silveira L, Koeberlein B, Franz S, Zentgraf H, Dong X, et al.
Modulation of MAPK pathways and cell cycle by replicating hepatitis B
virus:factors contributing to hepatocarcinogenesis. J Hepatol.
2007;47:325–37.
36. Xia H, Jianxiang C, Shi M, Gao H, Karthik S, Pratap SV, et al. EDIL3 is a novel
regulator of epithelial mesenchymal transition controlling early recurrence
of hepatocellular carcinoma. J Hepatol. 2015;63:863–673.
37. Fan ZC, Yan J, Liu GD, Tan XY, Weng XF, Wu WZ, et al. Real-Time
Monitoring of Rare Circulating Hepatocellular Carcinoma Cells in an
Orthotopic Model by In Vivo Flow Cytometry Assesses Resection on
Metastasis. Cancer Res. 2012;72:2683–91.
38. Yan J, Fan Z, Wu X, Xu M, Jiang J, Tan C, et al. Circulating tumor cells are
correlated with disease progression and treatment response in an
orthotopic hepatocellular carcinoma model. Cytometry A. 2015;87:1020–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Jiang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:38 Page 12 of 12
